|
The Cardiology Center Switzerland is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Cardiology Center Switzerland takes responsibility for the content, quality, and scientific integrity of these CME activities. This CME activity was planned and produced in accordance with the ACCME Essentials.
The Cardiology Center Switzerland designates each program listed below as approved for credit in category 1 credit toward the AMA Physician’s Recognition Award. Each physician should claim only those hours of credit that are spent in the educational activity.
- Conference Rapid News Summaries: 1.5 hours per day
- Acute Coronary Syndromes Subspecialties Online: 1.5 hours
- Lipids Subspecialties Online: 1.5 hours
- Acute Coronary Syndromes Audio Discussions Online: 0.5 hours per discussion
- Lipids Subspecialties Audio Discussions Online: 0.5 hours per discussion
- Late Breaking Clinical Trials I: 1.25 hours
- Hypertension: Implications of New Trials, Joint National Committee-7 and European Guidelines for Clinical Practice: 1.5 hours
- ACC'04 Meeting Highlights Session (Wednesday AM): 2.0 hours
The American Academy of Nurse Practitioners designates the program listed below as approved for contact hours of continuing education credit.
- Late Breaking Clinical Trials I: 1.25 hours
The AAPA accepts AMA category 1 CME credit for the PRA from organizations accredited by the ACCME. The program listed below is approved for continuing education credit.
- Late Breaking Clinical Trials I: 1.25 hours
Method of Participation and CME Credit
Please examine the program material, reflect on its content and complete the CME/CE Examination and Evaluation provided. Upon completion, you will be offered a certificate online which you can then view and print for your records.
Disclaimer
The Cardiology Center Switzerland is not responsible for statements made by any contributor. Statements or opinions expressed in this program reflect the views of the contributors and do not reflect the official policy of the Cardiology Center Switzerland.
For programs with question and answer components: the question and answer section of this product was designed to stimulate thinking and motivate readers to further research. Answers and commentary are based on the best judgment of the author at the time the question was written. New knowledge, insights and perspectives may cause the reader to disagree with an author's answer. The Cardiology Center Switzerland encourages thoughtful discussion and consideration of each question's answer and commentary.
Notice About Off-Label Use
The Late-Breaking Clinical Trials program may include discussion of drugs or devices, or uses of drugs or devices, that have not been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice.
ACCF is committed to the free exchange of medical education. Inclusion of any discussion in this program, including discussion on off-label uses, does not imply an endorsement by ACCF of the uses, products or techniques presented.
|
